Where We Invest

Stage & sector focus.

Sectors are selected for alignment between time-to-market, capital efficiency and commercial defensibility. We maintain flexibility but strongly prefer the combinations below.

Sector
Pre-Seed
Seed
Series A
Digital Health & AI in Life Sciences
1–3 YEARS TO MARKET
✓ Core target
✓ Core target
✓ Core target
DMDs & MedTech
3–6 YEARS TO MARKET
Exceptional cases only
✓ Core target
✓ Core target
TechBio
5–8 YEARS TO MARKET
Not at this stage
Exceptional cases only
✓ Core target

Check size: €100K–€2M at Pre-Seed and Seed; €2M–€5M at Series A. Approximately 50% of fund capital reserved for follow-on rounds up to €10M per company.

Portfolio Construction

~20 companies, three focus verticals.

60–65%

AI in Life Sciences & Digital Health

Rapid deployment, early investment, shortest time to market.

  • Clinical Intelligence & Decision Support
  • Connected Care & Data Platforms
20–25%

DMDs & MedTech

Regulatory hurdles, prototype and clinical validation stage.

  • Diagnostic & Imaging Technologies
  • Interventional & Therapeutic Devices
  • Advanced Bioengineering & Regenerative Tools
10–15%

TechBio

Deep tech, de-risked ventures with longer horizons.

  • Advanced Therapeutic Platforms
  • Precision Biology & Genomics
  • Computational & Enabling Technologies
Value-Add Beyond Capital

What founders get when we invest.

Business development

Pan-European network of payers, hospitals and commercial partners.

Team & venture building

Senior operators to complete founding teams at the right moment.

Regulatory support

EU MDR, IVDR, AI Act and HTA pathway expertise from day one.

IP support

Freedom-to-operate, prosecution strategy, portfolio valuation.

Clinical access

Warm introductions to research hospitals and reference sites.

EU grant leverage

Structuring non-dilutive capital alongside equity rounds.

EU market access

Cross-border commercial activation, not single-country plays.

Syndication

Tight relationships with seed-stage and growth-stage specialists.

Board craft

Institutional governance from seed round — not after Series B.

Pipeline & Deal Flow

~100 companies tracked.
5–6 first-year targets.

Our pipeline flows from premier European innovation frameworks — EIT Health, European Innovation Council, EIT KICs, European Digital Innovation Hubs, top university TTOs, HealthTech clusters, EU Chambers of Commerce and early-stage HealthTech funds we syndicate with.

EIC • EIT • EEN

Deep programmatic access built over a decade of operational leadership. EU’s Innovation Triangle is both dealflow source, and leverage for portfolio companies

EDIH • European Scaleup Fund • European Tech Champions

Alignment with other EU complementary instruments

Top European TTOs

Direct relationships with tech-transfer offices and research institutions.

Incubators & accelerators

Referral partnerships with leading HealthTech-focused programmes.

Chambers of Commerce

Broad SME dealflow access via national chamber networks.

Early-stage HealthTech funds

Syndicated dealflow with aligned pre-seed and seed specialists.

Building something in European HealthTech?

We review every inbound pitch. Early-stage founders who match the thesis above are welcome.

Submit your pitch